Prostate Specific Antigen

PSA testing is covered for men with lower urinary tract signs/symptoms, palpably abnormal prostate examination, abnormal laboratory or imaging suggesting prostate malignancy, and for monitoring established prostate cancer including detection of metastatic or persistent disease. Frequency limits include generally once per year for symptomatic patients (unless condition changes) and typically only a single test for in situ carcinoma unless abnormal (one repeat allowed); specified monitoring timepoints include 3–6 months post-prostatectomy and approximately six months after starting antiandrogen therapy.

"PSA testing is indicated to help differentiate benign from malignant prostate disease in men presenting with lower urinary tract signs or symptoms (e."

Sign up to see full coverage criteria, indications, and limitations.